Episurf Medical AB (publ) publishes Interim Report the first 6 months 2015
Second quarter, 1 April – 30 June 2015Group compared to 2014» Group net sales amounted to SEK 263,909 (22,157).» Other operating income amounted to SEK 1,110,025 (95,636).» Income after financial items amounted to SEK -11,384,072 (-9.320,493).» Episurf Medical’s quality management system was granted certification according to ISO 13485:12 and Annex II.» Rosemary Cunningham Thomas took over as the Company’s CEO.» The Episealer® condyle Solo implant was included in the Belgian reimbursement system.» The first compilation of monitoring data from the Company’s ongoing controlled